– UK, Brentford – GSK plc (LON: GSK / NYSE: GSK) today announced the appointment of Dr. Jeannie Lee (Ph.D.) to its Board as a Non-Executive Director effective on 4 March 2024.
“I am delighted to welcome Jeannie to GSK. Her deep expertise in scientific and medical innovation, including in the field of RNA biology and epigenetics which are key parts of GSK’s R&D approach, together with her experience in public health, will bring strong additional perspective to the Board.” said Board Chair, Sir Jonathan Symonds.
About Dr. Jeannie Lee
Dr. Jeannie Lee is Phillip A. Sharp, Ph.D., Endowed Chair in Molecular Biology and Acting Chair of the Department of Molecular Biology at the Massachusetts General Hospital. She is also a Professor of Genetics (and Pathology) at Harvard Medical School. She is a pioneer in the field of RNA Biology and its application to drug development and therapeutics. In addition to senior leadership positions held at both Harvard Medical School and the Massachusetts General Hospital, Dr. Lee co-founded Translate Bio and Fulcrum Therapeutics, two biotech companies specializing in RNA and epigenetic therapies.
Dr. Jeannie Lee is a Member of the National Academy of Sciences, the National Academy of Medicine, a Harrington Rare Disease Scholar of the Harrington Discovery Institute, a recipient of the Lurie Prize from the Foundation for the National Institutes of Health, an awardee of the Centennial Prize from the Genetics Society of America, the 2010 Molecular Biology Prize and the 2020 Cozzarelli Prize from the National Academy of Sciences, U.S.A, and a Fellow of the American Association for the Advancement of Science. She has also served on the Board of the Genetics Society of America.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
SOURCE: https://www.gsk.com/en-gb/home/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
